scholarly journals The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus

2006 ◽  
Vol 7 (4) ◽  
pp. 327-334 ◽  
Author(s):  
P L De Jager ◽  
R Graham ◽  
L Farwell ◽  
S Sawcer ◽  
A Richardson ◽  
...  
Lupus ◽  
2018 ◽  
Vol 27 (7) ◽  
pp. 1198-1201
Author(s):  
H Elsayed Mansour ◽  
S Gamal Arafa ◽  
W Abdelfatah Shehata

A 30-year-old female presented to the rheumatology outpatient clinic of the Internal Medicine Department, Ain Shams University Hospital, Cairo, Egypt, complaining of a large right leg ulcer consistent with pyoderma gangrenosum. There was history of recurrent attacks of bleeding per rectum of one-year duration. During hospitalization she noticed blurring of vision in the left eye with diffuse blackish discoloration of the feet and toes, consistent with small-vessel vasculitis. Colonoscopy with biopsy and histopathology confirmed the diagnosis of inflammatory bowel disease-ulcerative colitis (IBD-UC). Meanwhile, the patient fulfilled the SLICC classification criteria for systemic lupus erythematosus (SLE): recurrent oral ulcers, positive antinuclear antibody testing, proteinuria >0.5 gm/24-hour urine, positive test for lupus anticoagulant and consumed C3 complement component. Herein we report a rare case of coexistence of SLE and IBD-UC.


2016 ◽  
Vol 15 (11) ◽  
pp. 1034-1037 ◽  
Author(s):  
Dana Ben-Ami Shor ◽  
Shani Dahan ◽  
Doron Comaneshter ◽  
Arnon D. Cohen ◽  
Howard Amital

2019 ◽  
Vol 19 (02) ◽  
pp. 67-69
Author(s):  
Frances Feisi Sun ◽  
Nga Lai Chan ◽  
Tsz Ching Chan ◽  
Ka Long Leung ◽  
Yuk Wo Aaron Siu ◽  
...  

We report a 49-year-old lady with ulcerative colitis (UC) who subsequently developed systemic lupus erythematosus (SLE) ten years later. By reviewing the drug history and serum autoimmune panel, we hypothesize that systemic lupus erythematosus may occur in a patient with a history of inflammatory bowel disease as a coexisting disease, or triggered by drugs used in inflammatory bowel disease, such as disease-modifying anti-rheumatic drugs (DMARDs). This case raises the discussion that patients with Inflammatory bowel disease (IBD) may have a genetic predisposition for developing other autoimmune diseases, and explores the possibility of drugs used in the treatment of IBD as a trigger for SLE development. Being able to differentiate the two has important implications in management and prognosis.


1976 ◽  
Vol 5 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Stanley J. Korsmeyer ◽  
Robert G. Strickland ◽  
Arthur J. Ammann ◽  
Thomas A. Waldmann ◽  
Ralph C. Williams

Sign in / Sign up

Export Citation Format

Share Document